Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells

SIMPLE SUMMARY: The ToGA trial has demonstrated, in HER2-expressing patients, that unresectable and advanced gastric cancer, chemotherapy and trastuzumab in combination increase overall survival, even if it is still unclear why after one year the same patients are non-responsive to trastuzumab treat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Laterza, Maria Maddalena, Ciaramella, Vincenza, Facchini, Bianca Arianna, Franzese, Elisena, Liguori, Carmela, De Falco, Stefano, Coppola, Paola, Pompella, Luca, Tirino, Giuseppe, Berretta, Massimiliano, Montella, Liliana, Facchini, Gaetano, Ciardiello, Fortunato, de Vita, Ferdinando
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8150287/
https://ncbi.nlm.nih.gov/pubmed/34066144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13102339
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados